Vivos Therapeutics, Inc. Finance Lease, Liability, Undiscounted Excess Amount
Vivos Therapeutics, Inc. (VVOS) had Finance Lease, Liability, Undiscounted Excess Amount of $13.00 thousand as of 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Notes › Leases
us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount · last filed 2026-04-15
- 2025-12-31: Finance Lease, Liability, Undiscounted Excess Amount $13.00K.
| Period end | Finance Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $13.00K 10-K · filed 2026-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |